Home Machinery & Equipment Industrial Equipment Anti-obesity Medication Market

Anti-obesity Medication Market Size, Share & Trends Analysis Report By Product (Approved, Off Label), By Mechanism of Action (Peripherally Acting Drugs, Centrally Acting Drugs), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: March 09, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR5874DR | Pages: 160
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Anti-obesity Medication Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Approved
      1. Bupropion-naltrexone (Contrave)
      2. Liraglutide (Orlistat)
      3. Orlistat
        1. Xenical
        2. Alli
      4. Phentermine-topiramate (Qsymia)
      5. Semaglutide (Wegovy)
      6. Setmelanotide (Imcivree)
      7. Tirzepatide (Zepbound)
    2. Off Label
      1. Semaglutide (Xenical Alli)
      2. Liraglutide (Semaglutide (Wegovy))
      3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
      4. Others
  2. Anti-obesity Medication Market, By Mechanism of Action 2022-2034 (USD MILLION/ Units)
    1. Peripherally Acting Drugs
    2. Centrally Acting Drugs
  3. Anti-obesity Medication Market, By Distribution Channel 2022-2034 (USD MILLION/ Units)
    1. Retail Pharmacies
    2. Hospital Pharmacies
    3. Others
  4. Regional Anti-obesity Medication Market
    1. North America
      1. North America Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. North America Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. North America Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. U.S.
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Canada
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    2. Europe
      1. Europe Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. Europe Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. Europe Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. U.K.
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Germany
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. France
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. Spain
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Italy
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Russia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      10. Nordic
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      11. Benelux
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      12. Rest of Europe
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    3. APAC
      1. APAC Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. APAC Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. APAC Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. China
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Korea
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. Japan
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. India
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Australia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Singapore
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      10. Taiwan
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      11. South East Asia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      12. Rest of Asia-Pacific
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    4. Middle East and Africa
      1. Middle East and Africa Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. Middle East and Africa Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. Middle East and Africa Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. UAE
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Turkey
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. Saudi Arabia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. South Africa
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Egypt
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Nigeria
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      10. Rest of MEA
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
    5. LATAM
      1. LATAM Anti-obesity Medication Market By Product 2022-2034 (USD MILLION/ Units)
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
      2. LATAM Anti-obesity Medication Market By Mechanism of Action 2022-2034 (USD MILLION/ Units)
        1. Peripherally Acting Drugs
        2. Centrally Acting Drugs
      3. LATAM Anti-obesity Medication Market By Distribution Channel 2022-2034 (USD MILLION/ Units)
        1. Retail Pharmacies
        2. Hospital Pharmacies
        3. Others
      4. Brazil
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      5. Mexico
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      6. Argentina
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      7. Chile
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      8. Colombia
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
      9. Rest of LATAM
        1. Approved
          1. Bupropion-naltrexone (Contrave)
          2. Liraglutide (Orlistat)
          3. Orlistat
            1. Xenical
            2. Alli
          4. Phentermine-topiramate (Qsymia)
          5. Semaglutide (Wegovy)
          6. Setmelanotide (Imcivree)
          7. Tirzepatide (Zepbound)
        2. Off Label
          1. Semaglutide (Xenical Alli)
          2. Liraglutide (Semaglutide (Wegovy))
          3. Dulaglutide (Trulicity) Topiramate (Dulaglutide (Trulicity)
          4. Others
        3. Peripherally Acting Drugs
        4. Centrally Acting Drugs
        5. Retail Pharmacies
        6. Hospital Pharmacies
        7. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.